Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
Int J Urol. 2011 Jun;18(6):469-71. doi: 10.1111/j.1442-2042.2011.02757.x. Epub 2011 Mar 30.
We report a case of myelodysplastic syndrome (MDS) treated effectively with testosterone enanthate. A 70-year-old man was diagnosed with low-risk MDS in 1998, and he was first given methenolone acetate orally because of gradual progression of anemia and thrombocytopenia. However, this treatment was not effective, so we changed the treatment to testosterone enanthate because of his symptoms with late-onset hypogonadism. Three months after testosterone replacement therapy (TRT), anemia and thrombocytopenia had improved, and mean platelet count and hemoglobin had significant increases from 2.36 ± 0.45 × 10(4) to 3.83 ± 0.78 × 10(4) /µL, and from 11.7 ± 0.81 to 15.2 ± 1.00 g/dL, respectively, which contributed to a decrease in platelet transfusion requirement. Since then, the patient has been on a good clinical course. The present case suggests that testosterone enanthate administration could be an alternative treatment for men with MDS, even in the case where treatment with anabolic-androgenic steroids is not successful, and suggests another interesting effect of TRT on platelets.
我们报告了一例使用庚酸睾酮治疗有效的骨髓增生异常综合征（MDS）。一名 70 岁男性于 1998 年被诊断为低危 MDS，因贫血和血小板减少症逐渐加重，首先给予美替诺龙口服治疗。然而，由于他出现迟发性性腺功能减退的症状，治疗效果不佳，我们改用庚酸睾酮治疗。睾酮替代治疗（TRT）3 个月后，贫血和血小板减少症得到改善，平均血小板计数和血红蛋白分别从 2.36 ± 0.45×10(4) /µL 显著增加至 3.83 ± 0.78×10(4) /µL，从 11.7 ± 0.81 g/dL 增加至 15.2 ± 1.00 g/dL，从而减少了血小板输注的需求。此后，患者的临床状况良好。本病例提示，庚酸睾酮的使用可能是 MDS 男性患者的一种替代治疗方法，即使在使用合成代谢雄激素类固醇治疗不成功的情况下，并且提示 TRT 对血小板具有另一种有趣的影响。
